Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (46)	5/26/2000 10:53:00 AM
From: michael	Respond to of 139

If you are discouraged about phase III trials, it looks like sybb looks very very good. It said the product is working and this was given as an emergency. heres the news article SYNSORB Biotech Inc. Provides Emergency Supply of SYNSORB Pk To Hospitals In Walkerton Region For E. coli Outbreak CALGARY, Alberta, May 25, 2000 (BUSINESS WIRE) -- SYNSORB Biotech Inc. (Nasdaq:SYBB)(TSE:SYB.)("SYNSORB") today announced that it has received approval from Canadian Health Authorities to ship emergency supplies of SYNSORB Pk(R) to hospitals in the Walkerton, Ontario region in response to the serious E. coli outbreak in the area. There is no currently available therapy for patients suffering from E. coli infections. "SYNSORB is anxious to provide as much assistance to the people of Walkerton as we are able, through this compassionate use release of SYNSORB Pk(R)," said Dr. David Cox, President and CEO of SYNSORB. "It is our hope that SYNSORB's support will bring some resolution to the suffering of patients from this horrible disease, for which there is no satisfactory treatment currently available." SYNSORB Pk(R) is a drug designed to prevent serious complications associated with verotoxigenic E. coli (VTEC) infections (including E. coli O157:H7). Approximately 10% of patients who become infected with E. coli will go on to develop Hemolytic Uremic Syndrome (HUS), a severe and sometimes fatal kidney disease. Children and the elderly are most likely at risk of developing HUS, which can lead to a lifetime of dialysis and other serious complications. Approximately 5% of patients die from HUS. SYNSORB Pk(R) has been granted Fast Track Product designation by the US FDA, which is only given to those products that are designed to treat serious, life-threatening conditions for which there is no satisfactory treatment. VTEC is recognized as the fastest growing foodborne infectious disease in the world and is estimated to cause approximately 110,000 infections each year in the US. Sources of the infection include contaminated meat, fruit and vegetables, unpasteurized juice and milk, contaminated ground water, contaminated swimming pool water, and direct contact with infected people or animals. The disease is a leading cause of both acute and chronic renal insufficiency in children. SYNSORB is a Canadian-based pharmaceutical company dedicated to drug development and manufacturing. The Company's two late-stage products have been granted "Fast Track" designation by the FDA and are both based on SYNSORB's proprietary carbohydrate chemistry platform technology. SYNSORB Pk(R) is designed to prevent the progression to Hemolytic Uremic Syndrome (HUS) in children who have contracted verotoxigenic E. coli (VTEC) infections, including E. coli O157:H7. SYNSORB Cd(R) is a potential treatment for recurrent C. difficile antibiotic associated diarrhea (CDAD), a common hospital acquired infection. SYNSORB has built a cGMP-compliant manufacturing facility that has the capacity to meet or exceed the expected global demand for the Company's products. A pipeline of future products is accessible through SYNSORB's carbohybrid program. Shares of SYNSORB Biotech Inc. trade on the Toronto Stock Exchange in Canada (symbol "SYB") and on NASDAQ in the United States (ticker "SYBB"). This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. CONTACT: SYNSORB Biotech Inc. Cindy Gray, 403/270-1315 Fax: 403/283-5907 E-mail: Cgray@synsorb.com Website: www.synsorb.com or The Equicom Group Jason Hogan, 416/815-0700 ext 222 Fax: 416/815-0080 E-mail: Jhogan@equicomgroup.com URL: businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2000 Business Wire. All rights reserved. Distributed via COMTEX. KEYWORD: INTERNATIONAL CANADA INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL

To: Jim Oravetz who wrote (46)	5/30/2000 12:53:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 139

Progenics Identifies the HIV Docking Site on CCR5 Receptor TARRYTOWN, N.Y., May 30 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported today the discovery of the binding site for HIV on CCR5, a receptor protein found on cells that plays a critical role in HIV entry and infection. The new structural data provide researchers with a better understanding of how HIV infects cells and will contribute to the development of novel therapies for HIV. Conducted by a collaborative team of researchers from Progenics, Albert Einstein College of Medicine (Bronx, NY) and Rockefeller University (New York, NY), the study was reported in the current issue of the Proceedings of the National Academy of Sciences USA (Vol. 97, No. 11). To pinpoint the HIV binding site, Progenics' scientists and their collaborators tested the binding of synthetic CCR5 molecules to the HIV envelope glycoprotein gp120, which resides on the surface of the virus and mediates HIV entry. They observed that HIV bound a particular region or sequence of CCR5 and that it only occurred when the site contained sulfate groups at specific locations. Sulfate groups are naturally added to certain receptors like CCR5 in vivo. These findings were confirmed in laboratory tests, which showed that sulfated CCR5 peptides blocked HIV infection of target cells. Progenics has used this discovery as the basis of a new scientific discovery program focusing on the development of antiviral therapies targeting the CCR5 binding site on HIV. "These discoveries provide the first detailed description of the interactions between HIV and CCR5," said Ronald J. Prentki, President of Progenics. "We believe that these findings represent an important contribution to our understanding of how the virus infects cells and will ultimately advance the development of CCR5-based therapies for HIV infection." snip..... Jim